Neonatal Hearing Screening at Neonatal Intensive Care Unit
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03716362|
Recruitment Status : Not yet recruiting
First Posted : October 23, 2018
Last Update Posted : October 23, 2018
Hearing loss is one of the most common congenital anomalies . It has been shown to be greater than that of most other diseases and syndromes (eg, phenylketonuria, sickle cell disease) screened at birth. Data from the newborn hearing-screening programs in Rhode Island, Colorado, and Texas showed that 2-4 of every 1000 neonates have hearing loss.
Early Intervention at or before 6 months of age allows a child with impaired hearing to develop normal speech and language, alongside his or her hearing peers and can prevent severe psychosocial, educational, and language impairment.
One of the most high risk population are neonates who spend time in the newborn intensive care unit , exposed to high frequency ventilation, hyperbilirubinemia, low birth-weight, and exposed to ototoxic medications.
Auditory brainstem response , otoacoustic emissions , and automated Auditory brainstem response testing have all been used in newborn hearing-screening programs. otoacoustic emissions are fast objective, efficient, and frequency-specific measurements of peripheral auditory sensitivity are used to assess response of the outer hair cells to acoustic stimuli. To measure otoacoustic emissions, a probe assembly is placed in the ear canal, tonal or click stimuli are delivered, and the otoacoustic emissions generated by the cochlea is measured with a microphone .
|Condition or disease||Intervention/treatment|
|Hearing Loss||Device: Otoacoustic emissions device|
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Neonatal Hearing Screening at Neonatal Intensive Care Unit of Assiut University Hospital|
|Estimated Study Start Date :||November 1, 2018|
|Estimated Primary Completion Date :||October 2019|
|Estimated Study Completion Date :||November 2019|
|Neonates who will be admitted at Neonatal Intensive Care Unite||
Device: Otoacoustic emissions device
as a screening tool for Auditory brainstem response
- Prevalence of hearing loss in all neonates in Neonatal Intensive Care Unit [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03716362
|Women Health Hospital - Assiut university|
|Assiut, Egypt, 71111|